ATAI Life SciencesATAI
ATAI
About: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Employees: 54
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
228% more call options, than puts
Call options by funds: $1.27M | Put options by funds: $388K
54% more capital invested
Capital invested by funds: $19.3M [Q4 2024] → $29.7M (+$10.4M) [Q1 2025]
2.39% more ownership
Funds ownership: 8.66% [Q4 2024] → 11.05% (+2.39%) [Q1 2025]
10% less funds holding
Funds holding: 88 [Q4 2024] → 79 (-9) [Q1 2025]
19% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 21
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
374%
upside
Avg. target
$10
374%
upside
High target
$10
374%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio | 374%upside $10 | Buy Reiterated | 20 May 2025 |
Financial journalist opinion
Based on 15 articles about ATAI published over the past 30 days
Neutral
GlobeNewsWire
10 hours ago
HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Atai Life Sciences N.V.
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Atai Life Sciences N.V. (NASDAQ: ATAI ) related to the acquisition of Beckley Psytech Limited. Is it a fair deal?
Positive
Zacks Investment Research
6 days ago
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V.
Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors?
Positive
Zacks Investment Research
6 days ago
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
Here is how atai Life Sciences N.V. (ATAI) and Novartis (NVS) have performed compared to their sector so far this year.
Neutral
Business Wire
1 week ago
ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Atai Life Sciences N.V. (NASDAQ: ATAI) and Beckley Psytech Limited is fair to Atai shareholders. Halper Sadeh encourages Atai shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Atai and its board violated the fe.
Positive
Proactive Investors
1 week ago
atai Life Sciences gains maximum exposure to key psychedelic asset with Beckley Psytech merger
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) stock is poised to move higher following its planned merger with Beckley Psytech, as the combined entity will provide investors with maximum exposure to a promising therapy targeting treatment-resistant depression (TRD), analysts at Jefferies believe. BPL-003, Beckley's intranasal formulation of 5-MeO-DMT, is a short-acting psychedelic with the potential to deliver rapid and durable effects in TRD.
Positive
Proactive Investors
1 week ago
atai Life Sciences and Beckley Psytech to merge in all-share deal, stock pops
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares soared before Monday's opening bell after it announced it has inked a definitive agreement to merge with Beckley Psytech, a private clinical-stage biopharmaceutical company developing psychedelic-based therapies, in an all-share transaction valued at $390 million. The merger is contingent upon the achievement of pre-agreed success criteria in Beckley's ongoing Phase 2b trial of BPL-003 (mebufotenin benzoate), the company said.
Neutral
GlobeNewsWire
1 week ago
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
NEW YORK and BERLIN and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, and Beckley Psytech Limited (“Beckley”), a private clinical-stage biopharmaceutical company pioneering the next generation of mental health treatments, today announced a definitive agreement under which atai and Beckley plan to combine in an all-share transaction subject to pre-agreed BPL-003 (mebufotenin benzoate) Phase 2b success criteria.
Neutral
Proactive Investors
2 weeks ago
atai Life Sciences expects key trial data by mid-2025 - ICYMI
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company's clinical development progress in 2025, highlighting multiple upcoming trial readouts. Proactive: Hello, you're watching Proactive.
Neutral
GlobeNewsWire
2 weeks ago
atai Life Sciences to Participate in Upcoming Investor Conferences
NEW YORK and BERLIN, May 29, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that the Company's management team is scheduled to participate in the following investor conferences in June:
Positive
Zacks Investment Research
3 weeks ago
atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know
Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors?
Charts implemented using Lightweight Charts™